Speedel and Novartis win the Wall Street Journal Gold Award


Speedel welcomed the announcement that Speedel and Novartis have won the overall Gold Award in the seventh annual Wall Street Journal contest for Technology Innovation. This Gold Award was given to both companies for their work in discovering and developing SPP100 (aliskiren) the first direct renin inhibitor for treating hypertension. The compound received regulatory approval in 2007 in the US, Europe and Switzerland where it is marketed by Novartis under the trade names Tekturna and Rasilez respectively.

The Wall Street Journal received over 800 applications for these awards, and then narrowed the field down to about 150 entries which were reviewed by a distinguished panel of judges from business, research, and academic organisations. To qualify, technologies had to constitute a breakthrough from traditional methods, not just an incremental improvement. There was an overall Gold Silver and Bronze Award across all entries. Awards were all also made for each of the twelve categories reviewed, including the Medical/Biotech sector which Speedel and Novartis also won.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances